Compare Biogen Inc (BIIB) vs Ishares Msci Spain ETF (EWP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Ishares Msci Spain ETF — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Ishares Msci Spain ETF trades at $59.52. The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Biogen Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | EWP | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.63 | $60.28 |
52-Week Low | $122.68 | $43.90 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
EWP is trading at $58.94, down 0.86% over the past 24 hours. The technical outlook is bullish, with moving averages signaling strength, while oscillators remain neutral. A dividend of $0.92 is scheduled for payment on June 18, 2026. Recent news highlights European market dynamics, including ECB rate hikes and regional economic performance, which may influence this US-listed stock's sentiment.
The stock's outlook is supported by bullish technical signals, but fundamental data is unavailable, limiting valuation assessment. Key risks include reliance on European economic conditions and potential volatility from monetary policy shifts. Investor sentiment appears mixed, with technical strength offset by a lack of recent fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →
